作　者：Zheng X, Cheng M, Fu B, Fan X, Wang Q, Yu X, Sun R, Tian Z, Wei H.
Abstract：There remains a great need for effective therapies for lung cancer, the majority of which are non-small-cell lung cancers (NSCLC). Here we report the identification of a novel candidate therapeutic target, LunX, as a molecule overexpressed in primary NSCLC and lymph node metastases that is associated with reduced postoperative survival. Functional studies demonstrated that LunX overexpression promoted lung cancer cell migration and proliferation by interactions with the chaperone protein 14-3-3. Conversely, LunX silencing disrupted primary tumor growth, local invasion and metastatic colonization. The finding that LunX was expressed on cell membranes prompted us to generate and characterize LunX antibodies as a candidate therapeutic. Anti-LunX could downregulate LunX and reduce lung cancer cell proliferation and migration in vitro. Administered in vivo to mice bearing lung cancer xenografts, anti-LunX could slow tumor growth and metastasis and improve mouse survival. Together, our work provides a preclinical proof of concept for LunX as a novel candidate target for immunotherapy in lung cancer.

版权与免责声明：本网页的内容由收集互联网上公开发布的信息整理获得。目的在于传递信息及分享，并不意味着赞同其观点或证实其真实性，也不构成其他建议。仅提供交流平台，不为其版权负责。如涉及侵权，请联系我们及时修改或删除。邮箱：sales@allpeptide.com